OBJECTIVES: Predictive models for hepatocellular carcinoma (HCC) have been limited by modest accuracy and lack of validation. Machine-learning algorithms offer a novel methodology, which may improve HCC risk prognostication among patients with cirrhosis. Our study's aim was to develop and compare predictive models for HCC development among cirrhotic patients, using conventional regression analysis and machine-learning algorithms. METHODS: We enrolled 442 patients with Child A or B cirrhosis at the University of Michigan between January 2004 and September 2006 (UM cohort) and prospectively followed them until HCC development, liver transplantation, death, or study termination. Regression analysis and machine-learning algorithms were used to construct predictive models for HCC development, which were tested on an independent validation cohort from the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial. Both models were also compared with the previously published HALT-C model. Discrimination was assessed using receiver operating characteristic curve analysis, and diagnostic accuracy was assessed with net reclassification improvement and integrated discrimination improvement statistics. RESULTS: After a median follow-up of 3.5 years, 41 patients developed HCC. The UM regression model had a c-statistic of 0.61 (95% confidence interval (CI) 0.56-0.67), whereas the machine-learning algorithm had a c-statistic of 0.64 (95% CI 0.60-0.69) in the validation cohort. The HALT-C model had a c-statistic of 0.60 (95% CI 0.50-0.70) in the validation cohort and was outperformed by the machine-learning algorithm. The machine-learning algorithm had significantly better diagnostic accuracy as assessed by net reclassification improvement (P<0.001) and integrated discrimination improvement (P=0.04). CONCLUSIONS: Machine-learning algorithms improve the accuracy of risk stratifying patients with cirrhosis and can be used to accurately identify patients at high-risk for developing HCC.
OBJECTIVES: Predictive models for hepatocellular carcinoma (HCC) have been limited by modest accuracy and lack of validation. Machine-learning algorithms offer a novel methodology, which may improve HCC risk prognostication among patients with cirrhosis. Our study's aim was to develop and compare predictive models for HCC development among cirrhoticpatients, using conventional regression analysis and machine-learning algorithms. METHODS: We enrolled 442 patients with Child A or B cirrhosis at the University of Michigan between January 2004 and September 2006 (UM cohort) and prospectively followed them until HCC development, liver transplantation, death, or study termination. Regression analysis and machine-learning algorithms were used to construct predictive models for HCC development, which were tested on an independent validation cohort from the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial. Both models were also compared with the previously published HALT-C model. Discrimination was assessed using receiver operating characteristic curve analysis, and diagnostic accuracy was assessed with net reclassification improvement and integrated discrimination improvement statistics. RESULTS: After a median follow-up of 3.5 years, 41 patients developed HCC. The UM regression model had a c-statistic of 0.61 (95% confidence interval (CI) 0.56-0.67), whereas the machine-learning algorithm had a c-statistic of 0.64 (95% CI 0.60-0.69) in the validation cohort. The HALT-C model had a c-statistic of 0.60 (95% CI 0.50-0.70) in the validation cohort and was outperformed by the machine-learning algorithm. The machine-learning algorithm had significantly better diagnostic accuracy as assessed by net reclassification improvement (P<0.001) and integrated discrimination improvement (P=0.04). CONCLUSIONS:Machine-learning algorithms improve the accuracy of risk stratifying patients with cirrhosis and can be used to accurately identify patients at high-risk for developing HCC.
Authors: J M Llovet; J Bustamante; A Castells; R Vilana; M del C Ayuso; M Sala; C Brú; J Rodés; J Bruix Journal: Hepatology Date: 1999-01 Impact factor: 17.425
Authors: Ewout W Steyerberg; Andrew J Vickers; Nancy R Cook; Thomas Gerds; Mithat Gonen; Nancy Obuchowski; Michael J Pencina; Michael W Kattan Journal: Epidemiology Date: 2010-01 Impact factor: 4.822
Authors: Akbar K Waljee; Joel C Joyce; Sijian Wang; Aditi Saxena; Margaret Hart; Ji Zhu; Peter D R Higgins Journal: Clin Gastroenterol Hepatol Date: 2009-10-14 Impact factor: 11.382
Authors: A Singal; M L Volk; A Waljee; R Salgia; P Higgins; M A M Rogers; J A Marrero Journal: Aliment Pharmacol Ther Date: 2009-04-08 Impact factor: 8.171
Authors: Amit G Singal; Hema Manjunath; Adam C Yopp; Muhammad S Beg; Jorge A Marrero; Purva Gopal; Akbar K Waljee Journal: Am J Gastroenterol Date: 2014-01-21 Impact factor: 10.864
Authors: Lindsay Y King; Claudia Canasto-Chibuque; Kara B Johnson; Shun Yip; Xintong Chen; Kensuke Kojima; Manjeet Deshmukh; Anu Venkatesh; Poh Seng Tan; Xiaochen Sun; Augusto Villanueva; Angelo Sangiovanni; Venugopalan Nair; Milind Mahajan; Masahiro Kobayashi; Hiromitsu Kumada; Massimo Iavarone; Massimo Colombo; Maria Isabel Fiel; Scott L Friedman; Josep M Llovet; Raymond T Chung; Yujin Hoshida Journal: Gut Date: 2014-08-20 Impact factor: 23.059
Authors: Amit G Singal; Xilong Li; Jasmin Tiro; Pragathi Kandunoori; Beverley Adams-Huet; Mahendra S Nehra; Adam Yopp Journal: Am J Med Date: 2014-08-10 Impact factor: 4.965
Authors: Purva Gopal; Adam C Yopp; Akbar K Waljee; Jason Chiang; Mahendra Nehra; Pragathi Kandunoori; Amit G Singal Journal: Clin Gastroenterol Hepatol Date: 2013-10-02 Impact factor: 11.382